Hindi na matutuloy ang clinical trial sa Pilipinas ng World Health Organization (WHO) para sa gamot na acalabrutinib laban sa COVID-19.
Isang uri ng oral medication laban sa cancer ang acalabrutinib, na dinadagdag ng WHO sa listahan noong Oktubre.
“Hindi siya matutuloy. Nagbigay na ng recommendation ang WHO. It’s not going to be part of Solidarity Trial anymore,” ani Health Usec. Maria Rosario Vergeire.
Wala naman daw pasyenteng nabigyan ng naturang gamot, kaya inaasikaso na ng Department of Health (DOH) ang pagsasantabi sa dumating na supply.
“Gagawan ng disposal mechanism para magkaroon ng final disposition itong mga dumating na gamot.”
Ayon sa National Institutes of Health (NIH) ng US Department of Health and Human Services, ginamit na sa clinical trial ng Myelofibrosis, Ovarian Cancer, Multiple Myeloma, at Hodgkin Lymphoma ang acalabrutinib.
Noong Hunyo, lumabas din sa artikulo ng NIH na nagawang pabutihin ng gamot ang lagay ng ilang pasyente na diagnose ng severe respiratory distress dahil sa COVID-19.
“Within one to three days after they began receiving acalabrutinib, the majority of patients in the supplemental oxygen group experienced a substantial drop in inflammation, and their breathing improved,” nakasaad sa NIH article.
“These findings should not be considered clinical advice but are being shared to assist the public health response to COVID-19.”
As of October 2, higit 12,000 na pasyente ang na-recruit na sumali sa Solidarity Therapeutic Trials, na sinalihan naman ng 116 na bansa.
“The greater the number of patients enrolled, the faster results will be generated. WHO is facilitating access to thousands of treatment courses for the trial through donations from a number of manufacturers,” ayon sa WHO.
